Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

The FDA designates SH-110 as an orphan drug, offering a safer oral treatment option for glioma patients with swallowing ...

Pierre Fabre leads global development of tab-cel, an innovative therapy for EBV+ PTLD, with ongoing trials and potential FDA ...

During a live event, Sumanta K. Pal, MD, discussed second-line renal cell carcinoma therapies, in the context of a patient ...

Theresa Medina, MD, discusses the clinical potential of lifileucel, a tumor-infiltrating lymphocyte therapy, for patients with advanced melanoma.

A new FDA application for relacorilant shows promising survival benefits in treating platinum-resistant ovarian cancer, ...

An expert discusses how recent clinical advancements and biomarker-driven strategies are reshaping first-line treatment decisions in metastatic triple-negative breast cancer (mTNBC), emphasizing the ...

An expert discusses how emerging trial data, particularly from ASCENT-04, are reshaping first-line treatment strategies for PD-L1–positive metastatic triple-negative breast cancer (mTNBC) by ...

During a live event, Nelson J. Chao, MD, asked participants how they employ the currently approved treatments for chronic GVHD.

The FDA evaluates glofitamab and daratumumab for lymphoma and myeloma treatments, highlighting trial demographics and ...

Ayal Aizer, MD, MHS, discusses the findings of a phase 3 study investigating the use of stereotactic radiation vs whole-brain radiation in patients with 5 to 20 brain metastases.

Nicole A. Cipriani, MD, offers guidance for community oncologists regarding the role of BRAF p.V600E testing in patients with papillary thyroid carcinoma.